As part of my post on “The thyroid gland is a T3 shield,” I reviewed a research article by Ingbar and team from 1982. Wow. What a treasure. The title of this article is “Elevated serum thyroxine concentration in patients… Read More ›
In 2011, Gullo’s research team published a landmark study in thyroid therapy titled “Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients.” Gullo and colleagues examined the TSH, FT3 and FT4 levels and the FT3:FT4 ratios of 1,811 thyroidless patients… Read More ›
I would like to applaud a 2019 article by Mitsuru Ito and colleagues from the Center for Excellence in Thyroid Care at Kuma Hospital, Kobe, Japan. Dear researchers, your article, “Thyroid function related symptoms during monotherapy in athyreotic patients” showcased… Read More ›
A clinical trial comparing Armour Thyroid (NDT) and Levothyroxine (LT4) is now recruiting patients in the United States. The sponsor of the study is Allergan, the makers of Armour Thyroid in the United States. They hope to recruit 220 patients… Read More ›
There’s no surprise that patients and doctors would disagree about the incidence rate of hypothyroid symptoms in a given patient. “We have an average of 7.2 symptoms per patient” says the cohort of 262 patients. “No, you have an average… Read More ›
In this Part 3, I continue my rebuttal of a research article that blames thyroid patients for causing harm to themselves by making requests of doctors for tests and therapies.
In this post, I explain the good signs that thyroid patients’ self-advocacy is sometimes effective and is making a difference.
We all know a “thyroidectomy” is the surgical removal of a thyroid gland. Nobody removes a vital gland without a patient’s informed consent. If your medical system and doctor are ethical, you as a patient have the opportunity to weigh… Read More ›